As part of our Research Innovation Awards, we’re funding Professor Claire Lewis at the University of Sheffield to see if it's possible to train men’s own immune systems to fight back at prostate cancer and prevent it from returning. She explains the fascinating 'Trojan horse' science behind this new example of Immunotherapy research.

The Institute of Cancer Research has discovered a genetic mutation in samples of some men's tumours that could make them particularly susceptible to immunotherapy treatment. The researchers are now committed to running clinical trials to prove if their theory is right.

Preventing resistance to hormone therapy is a key goal for researchers trying to improve prostate cancer treatment. Now, research funded by us – thanks to your donations – has revealed that the immune system could have a part to play.

An early-stage trial of the immunotherapy drug, pembrolizumab, has proven it to be effective for a small number of men with incurable disease. We take a closer a look at how it works and what we're doing to bring the benefits of immunotherapy to many more men with prostate cancer.

BLOG: In 2013, the prestigious Science magazine nominated cancer immunotherapy as their ‘breakthrough of the year’. This came after positive results from clinical trials in skin cancer and leukemia patients showed its potential as a completely new way to treat cancer. Sophie Lutter investigates and asks if immunotherapy has a future as a way of treating prostate cancer.